The Most Comprehensive Urinary Mycotoxin Test on the Market

Shoreline, Washington, Sept. 22, 2026 -- US BioTek™ medical and diagnostic laboratory specializing in mold and environmental toxin detection, today announces the launch of its Mycotoxin Extensive Panel, the most comprehensive urinary mycotoxin test available on the market. The expanded mycotoxin test features 31 distinct clinical markers and advanced testing methodologies. It gives functional and integrative medicine practitioners broader diagnostic clarity, and grants patients a clearer view of potential mold exposure to better understand their symptoms and support better informed clinical conversations.

31 distinct clinical markers and advanced testing methodologies

As both practitioner and patient interest in environmental health and mold exposure continues to grow, the extended panel provides broader insight from a single urine sample, without adding complexity for the patient. The expanded urine mycotoxin test continues to measure the mycotoxins most commonly associated with mold exposure, including Ochratoxin A, Aflatoxins, Gliotoxin, Zearalenone, and macrocyclic Trichothecenes such as Satratoxins and Roridins, while adding 16 additional markers, among them Chaetoglobosin A, Citrinin, Sterigmatocystin, Patulin, and Fumonisins. These mold toxins have been found to cause a range of potential health effects, giving practitioners a comprehensive set of data to consider alongside a patient's symptoms, exposure history, and other clinical findings.

Beyond the increased number of markers measured, US BioTek Labs has enhanced the panel with a proprietary hydrolysis processing technology designed to address key considerations in urinary mycotoxin testing. Using highly sensitive LC-MS/MS technology, the enhanced methodology is designed to capture mycotoxins others miss due to masking from metabolite modifications and provide practitioners with a more complete picture from a single sample. Results are standardized to urinary creatinine.

“The expansion of our mycotoxin panel and methodologies underscores our commitment to diagnostic accuracy and rigorous laboratory standards,” said Jack Frausing, CEO of US BioTek, parent company of US BioTek Labs. “Serving as partners to both practitioners and patients, US Biotek Labs empowers informed clinical action, improving confidence in treatment decision-making.”

The launch also expands the scope of US BioTek Labs’ integrative testing suites

The launch also expands the scope of US BioTek Labs’ integrative testing suites, including the All-Tox Profile and the MOE-Tox Complete Profile, which evaluate mycotoxin exposure alongside environmental pollutants, heavy metals, and organic acids to measure total body burden and cellular mitochondrial function.

“For practitioners, the value of comprehensive testing is having more information to consider as part of the overall clinical picture,” said Marjorie Peak, ND, consulting physician for US BioTek Labs. “By expanding the number of markers measured and using an expanded methodology designed to capture a wider range of mycotoxin metabolites, the panel builds on US BioTek Labs’ existing testing capabilities and provides additional context to support clinical decision-making.”

For more information on this new mycotoxin panel, click here.

About US BioTek Laboratories

US BioTek Laboratories is a CLIA-certified and CAP-accredited clinical laboratory specializing in functional and integrative medicine testing. Founded in 1998 and a global leader in food sensitivity testing, US BioTek offers practitioners a comprehensive menu of food sensitivity, gastrointestinal, hormone, nutritional, and environmental toxin panels. With a commitment to identifying the underlying factors behind chronic health concerns, US BioTek supports clinicians with accurate testing, clinical consultation, and practitioner-focused service.